The goal of this observational study is to identify diagnostic biomarkers for neurosyphilis in patients with the condition. The main questions it aims to answer are: What plasma biomarkers are associated with neurosyphilis? What electrophysiological characteristics (EEG and eye movement) are linked to neurosyphilis? Researchers will compare biomarker data from plasma and gut microbiome analyses with electrophysiological findings to see if these factors can help diagnose neurosyphilis. Participants will: Provide clinical information such as age, gender, symptoms, and disease course Submit blood and urine samples for proteomics and metagenomic sequencing Undergo EEG and eye movement evaluations for electrophysiological analysis
Study Type
OBSERVATIONAL
Enrollment
360
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
RECRUITINGMeasurement of AIM2 inflammasome in peripheral blood.
This measure will assess the expression levels of the AIM2 inflammasome in peripheral blood samples from subjects using proteomics methods, mass spectrometry.
Time frame: Data will be collected at baseline, 6 months, and 12 months after enrollment.
Measurement of NFL and sTREM2 in cerebrospinal fluid.
This measure will evaluate the levels of neurofilament light chain (NFL) and myeloid cells 2 (sTREM2) in cerebrospinal fluid samples from subjects. The measurement will utilize techniques such as TRUST, TPPA and mass spectrometry to assess these biomarkers.
Time frame: Data will be collected at baseline, 6 months, and 12 months after enrollment.
Assessment of Cognitive Function using MoCA
This measure will evaluate cognitive function in subjects using the Montreal Cognitive Assessment (MoCA). The MoCA is a 30-point test that assesses multiple cognitive domains, including visuospatial and executive functions, naming, memory, attention, language, and orientation. Higher scores indicate better cognitive function, with a maximum possible score of 30. A score of 26 or above is considered within the normal range, while a score of 25 or below may indicate mild cognitive impairment.
Time frame: Cognitive assessments will be conducted at baseline and 6 months post-enrollment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.